SEC Tracker
Get the app

Yarrow Bioscience

YARW

Listing: 1 notice since Mar 2026 (newest Mar 11)

Dilution Known so far: 5.8M possible new shares (216.1% of today's 2.7M) · shelf room about $0 at the $32.0M float · not yet read: warrants, converts, options, ATM. Every source

Revenue $97K (+41%), diluted EPS −$3.51 in the quarter ended Jun 30, 2026, from a 10-Q filed .

Insiders No open-market insider buys or sells at Yarrow Bioscience in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders. Every trade

Next: earnings expected ~Nov 9; 10-Q expected ~Nov 12 (deadline Nov 16)

Get email alertsGet the app
Legal name
Yarrow Bioscience, Inc.
CIK
1566044

Notable10-Q filed

Quarter ended Jun 30, 2026: revenue $97K (+41%), diluted EPS −$3.51

From the 10-Q 0001566044-26-000010, as tagged in its XBRL, against the Jun 2025 quarter.

Read the 10-Q on EDGARTables over time

Cash runway and key numbers

About 7.5 quarters of cash at the average operating burn of the last 2 quarters, which would last to about May 2028.

Cash
$22.9M
Operating burn a quarter, average of the last 2 quarters
$3.0M

From the 10-Q 0001566044-26-000010 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.

Every line item over time, with Excel and CSV export

Get an email when Yarrow Bioscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What Yarrow Bioscience does

Yarrow Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need. Source

Products

  • repibresib gel Product

    A topically administered, small molecule pan-BD BET inhibitor designed as a 'soft' drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Source

    Key ingredient: pan-BD BET inhibitor

  • VYN202 Product

    An oral, small molecule BD2-selective BET inhibitor designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. Source

    Key ingredient: BD2-selective BET inhibitor

  • InhiBET BET Inhibitor Platform Platform

    A platform for the research, development, and commercialization of products containing certain BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Source

    Key ingredient: BET inhibitor compounds

From the 10-K filed Feb 27, 2026, Item 1, Business (its first part). Open the filing. Each line links to the passage it restates. The company's own description, summarized; not investment advice.

All filings

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

  9. 1 older filing, Jul 17

No open-market insider buys or sells at Yarrow Bioscience in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders. Every YARW insider trade

Financing and share filings

Other filings

  9. 4 older filings, Aug 3 to Jul 14

Older filings on EDGAR

Possible new shares

Known so far: 5.8M possible new shares (216.1% of today's 2.7M) · shelf room about $0 at the $32.0M float · not yet read: warrants, converts, options, ATM.

Not read yet: warrants, convertible notes, options and RSUs and an ATM program.

What could become new YARW shares

Listing compliance

0 open of 1 listing notice from 8-K item 3.01.

  • Mar 11, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices

Trading halts

No trading halts for YARW since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Fails-to-deliver: 66 shares on Aug 27, 2026, per SEC data

Coming up

  1. Earnings, expected
  2. 10-Q, expected (deadline Nov 16)

Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.

Yarrow Bioscience shares and listing

From the company's own filings; each row names its source. Not investment advice.

  • Listing compliance8-K item 3.011 noticestatus not stated, see the filings

Insider activity

No open-market insider buys or sells at Yarrow Bioscience in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders.

All YARW insider trades